OCUL – Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.OCUL
$6.40Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,408,146,304.00
EPSttm : -1.44
Ocular Therapeutix, Inc.
$6.40
3.90%$0.26
OCUL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.44
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.05
EPS Last/This Y
-0.02
EPS This/Next Y
-0.04
Price
6.64
Target Price
26.38
Analyst Recom
1.08
Performance Q
-34.06
Upside
-385.0%
Beta
1.23
Ticker: OCUL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | OCUL | 7.25 | 0.19 | 0.07 | 48124 |
| 2026-10-14 | OCUL | 7.21 | 0.19 | 0.19 | 48507 |
| 2026-10-15 | OCUL | 7.39 | 0.18 | 0.17 | 48586 |
| 2026-10-16 | OCUL | 6.86 | 0.18 | 0.01 | 49011 |
| 2026-10-19 | OCUL | 6.28 | 0.19 | 0.04 | 38945 |
| 2026-10-20 | OCUL | 6.65 | 0.18 | 0.18 | 40610 |
| 2026-10-21 | OCUL | 6.49 | 0.18 | 0.08 | 41327 |
| 2026-10-22 | OCUL | 6.62 | 0.18 | 0.13 | 41595 |
| 2026-10-23 | OCUL | 6.49 | 0.18 | 0.33 | 41683 |
| 2026-10-26 | OCUL | 6.48 | 0.18 | 0.52 | 42032 |
| 2026-10-27 | OCUL | 6.71 | 0.18 | 0.73 | 42151 |
| 2026-10-28 | OCUL | 7.33 | 0.18 | 0.02 | 42311 |
| 2026-10-29 | OCUL | 7.3 | 0.18 | 0.09 | 42745 |
| 2026-10-30 | OCUL | 6.97 | 0.18 | 0.29 | 43217 |
| 2026-11-02 | OCUL | 6.73 | 0.17 | 0.03 | 43337 |
| 2026-11-03 | OCUL | 6.83 | 0.17 | 0.93 | 43796 |
| 2026-11-04 | OCUL | 7.14 | 0.17 | 0.15 | 43875 |
| 2026-11-05 | OCUL | 6.43 | 0.17 | 0.03 | 43891 |
| 2026-11-06 | OCUL | 6.59 | 0.17 | 0.11 | 43979 |
| 2026-11-09 | OCUL | 6.86 | 0.17 | 0.09 | 44214 |
| 2026-11-10 | OCUL | 6.6 | 0.17 | 0.02 | 44295 |
| 2026-11-11 | OCUL | 6.64 | 0.17 | 0.07 | 44591 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | OCUL | 7.23 | 7.4 | - | -1.43 |
| 2026-10-14 | OCUL | 7.22 | 6.6 | - | -1.44 |
| 2026-10-15 | OCUL | 7.39 | 6.6 | - | -1.44 |
| 2026-10-16 | OCUL | 6.87 | 6.6 | - | -1.44 |
| 2026-10-19 | OCUL | 6.29 | 6.6 | - | -1.44 |
| 2026-10-20 | OCUL | 6.29 | 6.6 | - | -1.44 |
| 2026-10-21 | OCUL | 6.65 | 6.6 | - | -1.44 |
| 2026-10-22 | OCUL | 6.61 | 6.6 | - | -1.44 |
| 2026-10-23 | OCUL | 6.49 | 6.6 | - | -1.44 |
| 2026-10-26 | OCUL | 6.47 | 6.6 | - | -1.44 |
| 2026-10-27 | OCUL | 6.71 | 6.6 | - | -1.44 |
| 2026-10-28 | OCUL | 7.29 | 6.6 | - | -1.44 |
| 2026-10-29 | OCUL | 7.30 | 6.6 | - | -1.44 |
| 2026-10-30 | OCUL | 6.96 | 6.6 | - | -1.44 |
| 2026-11-02 | OCUL | 6.74 | 6.6 | - | -1.44 |
| 2026-11-03 | OCUL | 6.84 | 6.6 | - | -1.44 |
| 2026-11-04 | OCUL | 7.15 | 6.6 | - | -1.44 |
| 2026-11-05 | OCUL | 6.42 | 6.6 | - | -1.44 |
| 2026-11-06 | OCUL | 6.59 | 6.6 | - | -1.44 |
| 2026-11-09 | OCUL | 6.86 | 6.6 | - | -1.44 |
| 2026-11-10 | OCUL | 6.60 | 6.6 | - | -1.44 |
| 2026-11-11 | OCUL | 6.64 | 6.6 | - | -1.44 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | OCUL | -0.50 | 0.38 | 14.65 |
| 2026-10-14 | OCUL | -0.57 | 0.38 | 14.65 |
| 2026-10-15 | OCUL | -0.57 | 0.38 | 14.65 |
| 2026-10-16 | OCUL | -0.57 | 0.38 | 14.65 |
| 2026-10-19 | OCUL | -0.57 | 0.35 | 14.65 |
| 2026-10-20 | OCUL | -0.57 | 0.35 | 14.65 |
| 2026-10-21 | OCUL | -0.57 | 0.35 | 14.65 |
| 2026-10-22 | OCUL | -0.57 | 0.35 | 14.65 |
| 2026-10-23 | OCUL | -0.57 | 0.35 | 14.65 |
| 2026-10-26 | OCUL | -0.57 | 0.28 | 14.65 |
| 2026-10-27 | OCUL | -0.57 | 0.28 | 14.33 |
| 2026-10-28 | OCUL | -0.57 | 0.28 | 14.33 |
| 2026-10-29 | OCUL | -0.57 | 0.28 | 14.33 |
| 2026-10-30 | OCUL | -0.57 | 0.28 | 14.33 |
| 2026-11-02 | OCUL | -0.57 | 0.24 | 14.33 |
| 2026-11-03 | OCUL | -0.57 | 0.24 | 14.33 |
| 2026-11-05 | OCUL | -0.57 | 0.24 | 14.33 |
| 2026-11-06 | OCUL | -0.57 | 0.24 | 14.33 |
| 2026-11-09 | OCUL | -0.57 | 1.45 | 14.33 |
| 2026-11-10 | OCUL | -0.75 | 1.45 | 14.33 |
| 2026-11-11 | OCUL | -0.75 | 1.45 | 14.44 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.42
Avg. EPS Est. Current Quarter
-0.38
Avg. EPS Est. Next Quarter
-0.37
Insider Transactions
-0.75
Institutional Transactions
1.45
Beta
1.23
Average Sales Estimate Current Quarter
14
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
42
Growth Score
33
Sentiment Score
19
Actual DrawDown %
59.6
Max Drawdown 5-Year %
-72.8
Target Price
26.38
P/E
Forward P/E
PEG
P/S
29.09
P/B
3.32
P/Free Cash Flow
EPS
-1.46
Average EPS Est. Cur. Y
-1.44
EPS Next Y. (Est.)
-1.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-648.64
Relative Volume
0.96
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-80.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
OCUL
Healthcare
$6.66
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.7
Range 1M
36.8%
Sup Dist
2.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-12.1%
EPS NY
-3.2%
52W%
6.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+296.1% upside
Upside
+296.1%
Quality
42
OCUL — P/E HistoricalBiotechnology
Ocular Therapeutix, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 325
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL
Latest News
—
Caricamento notizie per OCUL…
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading